Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies

Print Friendly, PDF & Email

Ardini E, Siena S
ESMO Open. 2020 Sep;5(5):e000867. doi: 10.1136/esmoopen-2020-000867. PMID: 32907817; PMCID:PMC7481078.

Share this page

Facebook
Twitter
LinkedIn
Email
svg.e-font-icon-svg {display:none!important} .elementor-button-icon {display:none!important} .show-more, .show-more2 {display:none!important} img.pf-large-image.pf-primary-img.flex-width.pf-size-full.blockImage { display: none!important; }